Notch signaling: A hero or villain in the war against cancer?

Shireen Chikara, Katie M. Reindl

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The Notch signal transduction pathway regulates cell fate decisions throughout embryonic development. The mechanisms through which Notch signaling maintains cellular integrity are well understood. However, Notch signaling is more complex than previously thought as Notch is also involved in cancer where it functions as both an oncogene and tumor suppressor depending on the cellular context. Aberrant activation of oncogenic Notch is found in various cancers prompting the search for therapeutic agents to attenuate constitutively active Notch. However, there is also substantial evidence that Notch signaling suppresses tumor growth and progression, suggesting that Notch activators might be of therapeutic benefit in other cancers. This editorial describes the dual role of Notch signaling observed within and across multiple cancers. We highlight a study in non-small cell lung cancer cells (NSCLC) revealing a tumor suppressive role for endothelial cell Dll4-activated Notch1 and the underlying molecular mechanism involving suppression of PI3K signaling.

Original languageEnglish (US)
Pages (from-to)449-451
Number of pages3
JournalTranslational Lung Cancer Research
Volume2
Issue number6
DOIs
StatePublished - Jan 1 2013

Fingerprint

Neoplasms
Warfare
Phosphatidylinositol 3-Kinases
Oncogenes
Non-Small Cell Lung Carcinoma
Embryonic Development
Signal Transduction
Endothelial Cells
Therapeutics
Growth

Keywords

  • Dll4
  • Lung cancer
  • Notch
  • PI3K

ASJC Scopus subject areas

  • Oncology

Cite this

Notch signaling : A hero or villain in the war against cancer? / Chikara, Shireen; Reindl, Katie M.

In: Translational Lung Cancer Research, Vol. 2, No. 6, 01.01.2013, p. 449-451.

Research output: Contribution to journalArticle

@article{56c8247fbf564559808fc080494d9cad,
title = "Notch signaling: A hero or villain in the war against cancer?",
abstract = "The Notch signal transduction pathway regulates cell fate decisions throughout embryonic development. The mechanisms through which Notch signaling maintains cellular integrity are well understood. However, Notch signaling is more complex than previously thought as Notch is also involved in cancer where it functions as both an oncogene and tumor suppressor depending on the cellular context. Aberrant activation of oncogenic Notch is found in various cancers prompting the search for therapeutic agents to attenuate constitutively active Notch. However, there is also substantial evidence that Notch signaling suppresses tumor growth and progression, suggesting that Notch activators might be of therapeutic benefit in other cancers. This editorial describes the dual role of Notch signaling observed within and across multiple cancers. We highlight a study in non-small cell lung cancer cells (NSCLC) revealing a tumor suppressive role for endothelial cell Dll4-activated Notch1 and the underlying molecular mechanism involving suppression of PI3K signaling.",
keywords = "Dll4, Lung cancer, Notch, PI3K",
author = "Shireen Chikara and Reindl, {Katie M.}",
year = "2013",
month = "1",
day = "1",
doi = "10.3978/j.issn.2218-6751.2013.10.15",
language = "English (US)",
volume = "2",
pages = "449--451",
journal = "Translational Lung Cancer Research",
issn = "2226-4477",
publisher = "Society for Translational Medicine (STM)",
number = "6",

}

TY - JOUR

T1 - Notch signaling

T2 - A hero or villain in the war against cancer?

AU - Chikara, Shireen

AU - Reindl, Katie M.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The Notch signal transduction pathway regulates cell fate decisions throughout embryonic development. The mechanisms through which Notch signaling maintains cellular integrity are well understood. However, Notch signaling is more complex than previously thought as Notch is also involved in cancer where it functions as both an oncogene and tumor suppressor depending on the cellular context. Aberrant activation of oncogenic Notch is found in various cancers prompting the search for therapeutic agents to attenuate constitutively active Notch. However, there is also substantial evidence that Notch signaling suppresses tumor growth and progression, suggesting that Notch activators might be of therapeutic benefit in other cancers. This editorial describes the dual role of Notch signaling observed within and across multiple cancers. We highlight a study in non-small cell lung cancer cells (NSCLC) revealing a tumor suppressive role for endothelial cell Dll4-activated Notch1 and the underlying molecular mechanism involving suppression of PI3K signaling.

AB - The Notch signal transduction pathway regulates cell fate decisions throughout embryonic development. The mechanisms through which Notch signaling maintains cellular integrity are well understood. However, Notch signaling is more complex than previously thought as Notch is also involved in cancer where it functions as both an oncogene and tumor suppressor depending on the cellular context. Aberrant activation of oncogenic Notch is found in various cancers prompting the search for therapeutic agents to attenuate constitutively active Notch. However, there is also substantial evidence that Notch signaling suppresses tumor growth and progression, suggesting that Notch activators might be of therapeutic benefit in other cancers. This editorial describes the dual role of Notch signaling observed within and across multiple cancers. We highlight a study in non-small cell lung cancer cells (NSCLC) revealing a tumor suppressive role for endothelial cell Dll4-activated Notch1 and the underlying molecular mechanism involving suppression of PI3K signaling.

KW - Dll4

KW - Lung cancer

KW - Notch

KW - PI3K

UR - http://www.scopus.com/inward/record.url?scp=84948437190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948437190&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2218-6751.2013.10.15

DO - 10.3978/j.issn.2218-6751.2013.10.15

M3 - Article

C2 - 25806268

AN - SCOPUS:84948437190

VL - 2

SP - 449

EP - 451

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 6

ER -